Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

Performance of NOVO-B Novo Nordisk A/S | 59% in 12m

Compare NOVO-B with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Novo Nordisk A/S with its related Sector/Index XBI

Compare Novo Nordisk A/S with its related Sector/Index XBI

Performance Duell NOVO-B vs XBI

TimeFrame NOVO-B XBI
1 Day -1.05% -1.52%
1 Week 2.28% 3.45%
1 Month 3.67% 7.71%
3 Months 6.92% -2.11%
6 Months 31.0% 25.51%
12 Months 59.0% 6.37%
YTD 30.5% 1.05%
Rel. Perf. 1m -0.14
Rel. Perf. 3m 2.51
Rel. Perf. 6m -0.14
Rel. Perf. 12m 3.94

Is Novo Nordisk A/S a good stock to buy?

Yes, based on ValueRay Fundamental Analyses, Novo Nordisk A/S (CO:NOVO-B) is currently (May 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 87.14 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NOVO-B as of May 2024 is 1166.01. This means that NOVO-B is currently undervalued and has a potential upside of +29.08% (Margin of Safety).

Is NOVO-B a buy, sell or hold?

Novo Nordisk A/S has no consensus analysts rating. ValueRay therefore judges the recommendation based on the last 12 Month Returns of 58.98%.

In compare to SPDR S&P Biotech, NOVO-B made 52.61% more over the last 12 months. Due to the outperformance, it is recommend to buy NOVO-B.
Values above 0%: NOVO-B is performing better - Values below 0%: NOVO-B is underperforming

Compare NOVO-B with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY 0.63% -2.10% 12.75% 29.63%
US NASDAQ 100 QQQ 0.09% -2.42% 13.57% 21.63%
US Dow Jones Industrial 30 DIA 0.92% -2.50% 15.57% 36.96%
German DAX 40 DBXD 2.68% -1.30% 14.05% 42.21%
UK FTSE 100 ISFU 0.78% -6.13% 14.18% 43.61%
Shanghai Shenzhen CSI 300 CSI 300 1.17% -0.85% 27.71% 66.65%
Hongkong Hang Seng HSI -1.45% -19.61% 26.00% 64.34%
Japan Nikkei 225 EXX7 1.91% 4.17% 19.55% 47.17%
India NIFTY 50 INDA -0.83% -0.25% 13.46% 30.26%
Brasil Bovespa EWZ 1.84% -1.57% 32.87% 46.65%

NOVO-B Novo Nordisk A/S vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC 1.28% 0.36% 12.53% 21.50%
Consumer Discretionary XLY 1.94% -0.03% 23.70% 39.31%
Consumer Staples XLP 1.52% -2.91% 16.80% 53.40%
Energy XLE 1.08% 2.79% 16.92% 33.76%
Financial XLF 0.70% -3.38% 8.62% 25.91%
Health Care XLV 0.39% -2.01% 16.03% 45.48%
Industrial XLI 2.56% 0.19% 11.35% 30.65%
Materials XLB 1.94% 0.13% 15.02% 38.36%
Real Estate XLRE -0.23% -4.81% 21.40% 49.00%
Technology XLK -0.78% -2.85% 14.72% 20.67%
Utilities XLU 0.78% -9.22% 12.84% 46.30%
Aerospace & Defense XAR 1.51% -4.79% 15.50% 34.83%
Biotech XBI -1.17% -4.04% 5.53% 52.61%
Homebuilder XHB 2.60% -2.67% 0.53% 8.13%
Retail XRT 0.20% -3.79% 10.20% 33.79%

NOVO-B Novo Nordisk A/S vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO 0.06% 6.13% 22.25% 39.83%
Natural Gas UNG -13.34% -29.15% 53.52% 89.78%
Gold GLD 0.02% 1.82% 9.27% 37.58%
Silver SLV -9.44% -7.70% -1.33% 27.04%
Copper CPER -5.98% -11.04% -2.88% 23.72%

Returns of NOVO-B vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT 0.87% 0.95% 27.53% 66.50%
iShares High Yield Corp. Bond HYG 1.79% 1.15% 24.48% 48.13%
Does Novo Nordisk A/S outperform its market, is NOVO-B a Sector Leader?
Yes, over the last 12 months Novo Nordisk A/S (NOVO-B) made 58.98%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.37%.
Over the last 3 months NOVO-B made 6.92%, while XBI made -2.11%.
Period NOVO-B XBI S&P 500
1 Month 3.67% 7.71% 5.77%
3 Months 6.92% -2.11% 6.32%
12 Months 58.98% 6.37% 29.35%